NAD, NAD+ Levels in the Blood
Conditions
Keywords
NAD Supplementation, NAD
Brief summary
This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Interventions
DIETARY_SUPPLEMENTQualia NAD⁺ version 1
Qualia NAD+ version 1 manufactured by Qualia Life Sciences
DIETARY_SUPPLEMENTQualia NAD⁺ version 2
Qualia NAD+ version 2 manufactured by Qualia Life Sciences
DIETARY_SUPPLEMENTPlacebo
Rice Flour
Sponsors
Qualia Life Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study. Healthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks/shots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study
Exclusion criteria
Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Between-group change in intracellular NAD⁺ levels | 28 days | To assess between-group differences in the change in intracellular NAD⁺ levels from baseline to Week 4 following supplementation with Qualia NAD version 1, Qualia NAD version 2, or placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Aging-Related Symptoms (AMFS scores) | 4 weeks | To evaluate within-group and between-group differences in the change in Aging Male/Female Symptom (AMFS) total and sub-scale scores. |
| RAND SF-36 Scale Scores | 4 weeks | To assess within-group and between-group differences in RAND SF-36 domain scores. |
| Side effect profile as measured by a custom Safety and Tolerability survey | Week 1, 2, 3, and 4 | To evaluate side effect profiles using a custom Safety and Tolerability survey. |
| Within-group differences in the change in intracellular NAD⁺ levels | 4 weeks | To assess within-group differences in the change in intracellular NAD⁺ levels |
Countries
United States
Contacts
Primary ContactWilliam Scuba
Outcome results
None listed